TELAVANCIN

Search structure
Trade Names:
Synonyms:
Status: Approved (2009)
Entry Type: Small molecule
Molecule Category: Parent
ATC: J01XA03
UNII: XK134822Z0

Structure
InChI Key ONUMZHGUFYIKPM-MXNFEBESSA-N
Smile CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](Oc3c4cc5cc3Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c5cc(O)c(CNCP(=O)(O)O)c(O)c5-c5cc3ccc5O)[C@H](O)c3ccc(c(Cl)c3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O
InChI
InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C80H106Cl2N11O27P
Molecular Weight 1755.66
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Bacteremia 3 D016470 ClinicalTrials
Pneumonia, Bacterial 3 D018410 ClinicalTrials
Staphylococcal Skin Infections 3 D013207 ClinicalTrials
Gram-Positive Bacterial Infections 2 D016908 ClinicalTrials
Infections 2 D007239 ClinicalTrials
Renal Insufficiency, Chronic 1 D051436 ClinicalTrials

Related Entries

Scaffolds

Salt

Side Effects from Label

Side effects Relative Frequency (%) Labels
Gastrointestinal disorders Dysgeusia 33.0
Gastrointestinal disorders Nausea 27.0
Gastrointestinal disorders Nausea 15.0
Gastrointestinal disorders Vomiting 14.0
Skin and subcutaneous tissue disorders Pruritus 13.0
Gastrointestinal disorders Diarrhoea 8.0
Gastrointestinal disorders Diarrhoea 7.0
Gastrointestinal disorders Dysgeusia 7.0
Gastrointestinal disorders Vomiting 7.0
Cardiac disorders Dizziness 6.0
Skin and subcutaneous tissue disorders Pruritus 6.0
Pruritus generalised 6.0
Skin and subcutaneous tissue disorders Dermatitis 5.0
Gastrointestinal disorders Nausea 5.0
Skin and subcutaneous tissue disorders Rash 5.0
Renal failure acute 5.0
Gastrointestinal disorders Vomiting 5.0
General disorders and administration site conditions Chills 4.0
Skin and subcutaneous tissue disorders Dermatitis 4.0
General disorders and administration site conditions Infusion site pain 4.0
Gastrointestinal disorders Nausea 4.0
Skin and subcutaneous tissue disorders Rash 4.0
Renal failure acute 4.0
Gastrointestinal disorders Vomiting 4.0
General disorders and administration site conditions Decreased appetite 3.0
General disorders and administration site conditions Infusion site erythema 3.0
Pruritus generalised 3.0
Gastrointestinal disorders Abdominal pain 2.0
General disorders and administration site conditions Chills 2.0
General disorders and administration site conditions Decreased appetite 2.0
Gastrointestinal disorders Gastrointestinal pain 2.0
Multi-organ failure 1.0

Cross References

Resources Reference
CAS NUMBER 372151-71-8
ChEBI 71229
ChEMBL CHEMBL507870
DrugBank DB06402
DrugCentral 4116
EPA CompTox DTXSID10873383
FDA SRS XK134822Z0
Guide to Pharmacology 10925
PubChem 3081362
SureChEMBL SCHEMBL8287015
CONTENTS